- Home
- LUCD vs CLLS Comparison
LUCD vs CLLS Comparison
Compare LUCD & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- CLLS
- Stock Information
- Founded
- LUCD 2018
- CLLS 1999
- Country
- LUCD United States
- CLLS France
- Employees
- LUCD N/A
- CLLS N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- LUCD Health Care
- CLLS Health Care
- Exchange
- LUCD Nasdaq
- CLLS Nasdaq
- Market Cap
- LUCD 135.6M
- CLLS 144.4M
- IPO Year
- LUCD 2021
- CLLS 2007
- Fundamental
- Price
- LUCD $1.25
- CLLS $1.49
- Analyst Decision
- LUCD Strong Buy
- CLLS Buy
- Analyst Count
- LUCD 4
- CLLS 3
- Target Price
- LUCD $3.88
- CLLS $6.67
- AVG Volume (30 Days)
- LUCD 1.1M
- CLLS 48.8K
- Earning Date
- LUCD 05-14-2025
- CLLS 05-12-2025
- Dividend Yield
- LUCD N/A
- CLLS N/A
- EPS Growth
- LUCD N/A
- CLLS N/A
- EPS
- LUCD N/A
- CLLS N/A
- Revenue
- LUCD $4,173,000.00
- CLLS $54,747,000.00
- Revenue This Year
- LUCD $98.50
- CLLS $48.52
- Revenue Next Year
- LUCD $208.02
- CLLS $5.17
- P/E Ratio
- LUCD N/A
- CLLS N/A
- Revenue Growth
- LUCD 39.89
- CLLS 351.26
- 52 Week Low
- LUCD $0.68
- CLLS $1.10
- 52 Week High
- LUCD $1.80
- CLLS $2.81
- Technical
- Relative Strength Index (RSI)
- LUCD 44.52
- CLLS 53.80
- Support Level
- LUCD $1.21
- CLLS $1.46
- Resistance Level
- LUCD $1.70
- CLLS $1.60
- Average True Range (ATR)
- LUCD 0.12
- CLLS 0.08
- MACD
- LUCD 0.01
- CLLS -0.01
- Stochastic Oscillator
- LUCD 27.42
- CLLS 65.26
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.